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1. Introduction 
Colorectal cancer (CRC) is the most common malignancy of the gastrointestinal tract. In the 
United States, it is the third most commonly diagnosed cancer, next only to breast and lung. It 
is the second most common cause of cancer-related death both in the USA and in the UK. 
(www. cancer. org, O’Connell et. al. 2004a, Leff et. al. 2007). Its incidence has risen rapidly in 
Asia to pose a problem (Yuen et. al. 1997, Huang et. al. 1999, Mohandas et. al. 1999, Yiu et. al. 
2004, Goh et. al. 2005,Gupta et. al. 2010). Sung et. al. (2005) in a review on CRC in Asia stated 
that many Asian countries, e. g., China, Japan, South Korea, Singapore have experienced an 
increase of two to four times in CRC incidence during the past few decades. In Hong-Kong 
CRC is the second most common cancer and the third most common cause of cancer death 
(Yuen et. al. 1997). Tamura et. al. (1996) in a Japanese study reported that age adjusted 
incidence for CRC per 100,000 population were 12. 6 and 8. 7 for males and females 
respectively in 1974, 20 and 13. 6 in 1980, 42. 5 and 25. 6 in 1991. Bae et. al. (2002) estimated on 
the basis of Korean data, that the expected number of cancer deaths in Korea showed an 
increasing trend for CRC, although the same did not hold for all cancers. In Iran, age adjusted 
CRC incidence per 100,000 population per year increased from 1. 61 in 1970-80 to 4. 2 in 1990-
2000 in men and 2. 35 to 2. 72 for women (Hosseini et. al. 2004). The rising trend is more 
striking in affluent than in poorer societies and differs substantially amongst ethnic groups. 
Changes in dietary habits and lifestyle are recognized causes. Genetic characteristics of a 
population mediate the effect of life style change into disease propensity (Lin et. al. 2010).  
Although the common perception is that it is a disease of an older person, there have been 
many reports from different parts of the world on CRC in the young adults (Bulow 1980, 
Denmark; Ohman 1982, Sweden;Jarvinen and Turunen 1984, Finland; Ibrahim and Karim 
1986, Lebanon; Adloff et. al. 1986, France; Isbister and Fraser 1990, New Zealand; Yuen et. al. 
1997, Hong-Kong; Fante et. al. 1997, Italy; Ashenafi 2000, Ethiopia; deSilva et. al. 2000, 
Srilanka; Paraf and Jothy 2000, Canada; Turkiewicz et. al. , 2001, Australia; Singh et. al. 
2002a, Nepal; Kam et. al. 2004, Malayasia; Frizis et. al. 2004, Greece; Guraya and Eltinay2006, 
Saudi Arabia; Fazeli et. al. 2007, Iran; Karsten et. al. 2008, USA; Gupta et. al. 2010, India). 
O’Connell et. al. (2004a) have reviewed the literature. The proportion of patients in the 
young group in a population of CRC patients was significantly larger in reports from Asia 
and Africa, as compared to the Western reports.  
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The definition of ‘Young adults’ varies, to a small extent, in the literature. Majority of articles 
defined ‘young’ as <40 years, although upper limits of 50 years, 35 years and 30 years have 
also been used. O’Connell et. al. (2004a) estimated the average value of incidence of CRC in 
the young adults (<40 years) in the population of all CRC patients as 7% and adjusted it to 
6%, when outliers were removed. It has been suggested (Hamilton 2005) that the adjustment 
was ‘too small’ and a more realistic estimate was an average of 2. 2%. Leff et. al. (2007) gave 
an estimate of 2-3%. About 0. 1% of all CRC patients were diagnosed <20 years of age, ~1% 
between 20-34 years, ~4% between 35-44 years and a further ~12% between 45-54 years. 
These average figures reflect the extent of the problem in the West. The figures from Asian 
and African countries are considerably higher, a quarter or a half of a study group of CRC 
patients may belong to the under-40 group (Ashenafi 2000, Ethiopia; deSilva et. al. 2000, 
SriLanka; Singh et. al. 2002a, Nepal; Guraya and Eltinay 2006, Saudi Arabia; Gupta et. al. 
2010, India). Numerical values given later will establish that the problem of CRC in the 
young adult in the developing world is alarming.  
We now cite reports, from the West (USA, France, Scotland) and from Asia (Iran, Hong Kong), 
in which the incidence of the disease amongst the young adults has been studied in the same 
population over a period of time. O’Connell et. al. (2003) noted that in the USA, colon cancer 
incidence in older patients (60 + years) remained stable in the period 1973-1999 while rectal 
cancer incidence decreased by 11%. In the group of younger patients (20-40 years) colon cancer 
incidence increased by 17%, while rectal cancer incidence rose by 75% in the period 1973-1999. 
The improvement in the older age group is a reflection of more efficient cancer screening in the 
USA, a result of improved awareness of the disease. It is possible that relative ignorance about 
the problem of CRC in the young adult is responsible for the fact that the problem has 
worsened over the years. Other issues namely difference in molecular genetics, may also be 
present. In Iran, Hosseini et. al. (2004) defined the younger group as <60 years, compared 
figures in two 10 year periods 1970-1980 and 1990-2000 and found an increased proportion of 
< 60 years CRC patients (in a population of all CRC patients) in the latter decade, 37. 5% as 
against 70%. An increase in proportion of the young CRC patients was noted over a prolonged 
time span. Mitry et. al. (2001) from France reported that below-45 age standardized incidence 
rates doubled in the period 1976-1982 and then again in the period 1983-1989, in both genders 
and stabilized thereafter. In Hong-Kong, the overall incidence in > 50 years group increased at 
a rate of 4% a year during 1978-87, whereas in Scotland a higher overall incidence remained 
stable during this period (Yuen et. al. 1997).  
O’Connell et. al. (2004b) in a study of American patients found that young (20-40 years) colon 
cancer patients tend to have later-stage and higher-grade tumours. However they have 
equivalent or better 5 year cancer-specific survival compared to 60+ older group, an 
apparently paradoxical result. Although most reports agree on a more severe advanced 
disease at presentation in the young (Adloff et. al. 1986, Cusack et. al. 1996, Nath et. al. , 2009) 
and many also agree with the opinion that prognosis is not poorer in the young (Jarvinen and 
Turunen 1984, Turkiewicz et. al. 2001, Karsten et. al. 2008) some reports (Moore et. al. 1984, 
Adkins et. al. 1987, Okuno et. al. 1987, Singh et. al. 2002a) do not share the view that prognosis 
is ‘equivalent or better’. Inspite of this difference in assessment, a favourable prognosis in 
many studies should inspire more aggressive detection and treatment for the young.  
The genetic basis of CRC has been investigated in recent years. A satisfactory understanding 
of the disease, tumour characteristics, relationship of disease susceptibility with age and 
issues related to survival rely on an understanding of the link between molecular genetics 
and disease. A complete resolution of this relation is a tall order, but a modest beginning is 
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being made. Intelligent choice of treatment protocol, surgical as well as chemotherapeutic is 
also influenced by research on molecular genetics of CRC (Liang and Church 2010). 
Hereditary CRC usually occurs at a relatively young age, between 25 and 55 years in 
individuals with family history of CRC. Individuals who inherit the predisposing cancer 
gene have a greater chance of developing the disease (Murday and Slock 1989, Lynch et. al. 
1991, Lynch and de la Chapelle 2003, Ewart Toland, 2012). The importance of family history 
in determining susceptibility to CRC in the young has been stressed in the literature (St. 
John et. al. 1993, Fuchs et. al. 1994, Turkiewicz et. al. 2001). There exist literature reports that 
identify genetic factors in younger CRC patients which differ from those in older patients 
and may be responsible for greater cancer susceptibility of the younger patients (Farrington 
et. al. 1998, Chan et. al. 1999, Morris et. al. 2007, Berg et. al. 2010, Lin et. al. 2010).  
In this essay, we focus on the issue of CRC in young age, with particular reference to 
developing countries. The relative incidence figures of CRC in the young patients as 
compared to older patients in different parts of the world are given. These figures, in greater 
detail are given in the Indian context (section 2). Disease stage at presentation and tumour 
characteristics of younger patients, often in comparison with the older ones in different 
countries are then summarized (section 3). A brief reference to de novo cancer in Asians 
(section 4) is followed by a discussion of some recent genetic studies in the young (section 
5). Section 6 contains a discussion on prediosposing factors and section 7 has focus on 
prognosis in the young. The paper concludes (section 8) with a brief reference to the effect of 
recent molecular genetic research on treatment protocol.  
2. Incidence amongst young adults 
The relative incidence of CRC in the younger group varies significantly from one country to 
another. As cited above, it is typically 2-3% in the West. Other European figures are: Fante et. 
al. (Italy): 1%; Endreseth et. al. (Norway):6%; Ohman (Sweden): 4%; Adloff et. al. (France): 
3%; Yilmazlar et. al. (Turkey): 20%. The corresponding figures are much higher from several 
Asian and African countries: Nath et. al. (India): 35. 6%, <40 yrs; Gupta et. al. (India): 
39%,<40 years; Singh et. al. (South Asia): 23%,<40 years (with a maximum incidence in 40-60 
years, a decade earlier than Western figures): study period 1975-1981; Soliman et. al. (Egypt): 
35. 6%,<40 yrs; Ashenafi (Ethiopia): mean age 47 years (61. 4% <50years, 36% <40 yrs,16% 
<30 yrs) in two 5 year periods with a 10 year gap; Guraya and Eltinay (Saudi Arabia): study 
period 1999-2004,63% <40 yrs, mean age 44years, peak incidence 30-39 years; Hosseini et. al. 
(Iran): 70% (<60 years):study period 1990-2000; Chew et. al. (Singapore):25% <40 years; 
Singh et. al. (Nepal): 28. 6% <40 years; de Silva et. al. (Sri Lanka): 19. 7% <40 years. Some of 
these references are detailed in Table 1. In Egypt, more than half of all CRC patients are 
below-50, patients under-30 constitute 22% of the population of all CRC patients (Soliman et. 
al. 1997). Qing et.al. (2003) in a comparative study of American and Chinese patients (1990-
2000) reported that the mean age at diagnosis of 690 American patients was 69 years (20-91 
years) and that of 870 Chinese patients was 48. 3 years (13-84 years); peak incidence was 70-
79 years in Whites and 50-59 years in Orientals. The conclusion is that the Orientals are 
affected by the disease at a younger age. The same theme emerges from recent data from 
several Indian hospitals which includes our own recent work (Gupta et. al. 2010). In a period 
spanning 8 years (2000-2008), we found the ratio of under-40 to above- 40 years age group to 
be 0. 64. The study group comprised of 305 patients in SSKM Hospital, Kolkata, India, a 
premier referral Hospital. The values reported by three premier Oncology centers located  
in two cities in India and in another report by Pal (2006), based on work done 
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Sr. 
No.  
Reference, 
Period of study 
Age profile Disease stage Tumour characteristics 
1 
Lee 
1968-91 
62 patients, 
<40yrs 
Dukes’ A:8%, 
B:20%, C:23%, 
D:48%.  
Half of stage D patients 
and 20% of lower stage 
patients (p=0. 037)  
had high grade lesions. 
2 
Minardi, 
1976-97 
37 patients, 
<40yrs 
Dukes’ C:37%, 
D: 22%.  
Mucinous tumour : 
42%; moderate and 
poor differentiation : 
84% 
3 Cusack 
186 patients, 
<40yrs 
Dukes’ C & D: 
65. 6%.  
Poorly differentiated 
tumour in 41%, signet-
ring cell tumours in 11. 
1%, infiltrating tumour 
leading edges in 69%  
of young patients. 
Aggressive tumour 
biology with higher 
frequency in <40yr 
patients  
(p<0. 001), potentially 
metastatic. 
4 
Bedikian, 
1944-1977 
2609 
patients,<50yrs 
age; 183 
aged<40 yrs. 
Comparison 
between<30yr 
and 30-39yr 
age group and 
with yet  
older age 
group 
96% of < 40 years 
group had 
carcinoma 
extending beyond 
colonic wall.  
Moderate and poorly 
differentiated 
neoplasms (80%) and 
mucinous variety  
(33%) in young. 
5 
Beckman  
1943-1977 
69 patients: 20-
39yrs 
67% Dukes’  
C and D 
Mucinous variety 
(28%). 
6 Varma 
A review: 
all age groups 
Advanced stage 
more frequent in 
the young.  
Greater frequency of 
mucinous tumour in 
the young. 
7 
Cozart, 
Unusual Case 
Registry  
1992-93 
55 patients, 
<30yrs 
62% Dukes’  
C and D 
Poorly differentiated 
/mucinous variety: 
33% 
8 Howard 
801 patients 
including 
<40yrs group 
Advanced signs 
and stages more 
frequent in the 
young.  
Greater frequency of 
mucinous variety in the 
young 
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9 
Adkins,  
1973-1984 
705 patients; 
45 patients, 
<35yrs 
In the younger 
group: 
Dukes’ A:2,B:8, 
C: 28, D: 7 
patients.  
19: poorly 
differentiated,19:  
well or moderately 
differentiated 
 tumour 
10 
Moore,  
1967-1981 
3. 2% of 1909 
patients <40yrs 
Higher incidence 
of advanced 
disease, especially 
in second or third 
decades.  
Greater incidence of 
mucinous variety  
(32. 3% in young  
vs. 8. 6% in the  
whole study  
group). Poorly 
differentiated  
tumour: 98%;  
distant metastases in 
one-third patients.  
Vascular (24%)  
and perineural  
(11%) invasion in the 
young. 
11 
Karsten. , 
1998-2005 
Younger 
group: 
41 patients 
<40yrs 
Older group : 
>60 yrs 
Advanced stage: 
T-3/4 lesion in 87. 
8% of young/63% 
in older group 
(p=0. 002).  
Poorly differentiated, 
(p=0. 003),  
mucin secreting/ 
signet ring  
(p=0. 005), 
more common in the 
young 
12 
Fairley, 
1998-2001 
Cancer Registry 
(NPCR,SEER)* 
All age groups 
Young:20-49yrs 
Less localized, 
more aggressive 
disease in terms of 
stage in the young 
(20-49yrs) 
Incidence of poorly 
differentiated  
tumour in young 
(<50yrs) (i) twice as 
high as well 
differentiated  
ones in the  
young (ii)60%  
higher than that 
 for well  
differentiated  
cancers in  
the old 
13 
Lichtman 
1987-1991 
57. 2% <70yrs 
Dukes’ C and D 
more frequent at a 
lower age 
(p=0. 03).  
Mean Age A/B-1 
67. 7 yrs, B-2 70. 
1yrs, C/D 63. 9yrs  
Grade not  
related to age 
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Dozois,  
1976-2002 
1025 
patients,<50yrs; 
Mean age 42. 
4±6. 4 years 
51% colon, 49% 
rectal (largest 
cohort of 
young-onset 
patients 
without genetic 
predisposition) 
70% colon,  
60% rectal:  
stage C&D 
Colon Cancer: 
Mucinous(11%) & 
Signet cell (2%) 
Grade 2+3 for both 
rectum & colon cancer: 
~87% 
15  
Behbehani 
11 yrs period 
pre-1980 
<40 years 
group: 
56 patients 
Advanced stage 
C&D: ~90% in 
young  
~50% in general 
population 
Poor differentiation: 
21% in young, 8% in 
general population 
*NPCR: National Program of Cancer Registries; SEER: Surveillance, Epidemiology and End Results 
Table 1. Summary of references in the literature on stage and tumour characteristics in the 
USA 
in the same referral hospital where Gupta et. al. (2010) worked are 0. 58, 0. 63, 0. 45, 0. 62. 
Average of these five ratios is 0. 52, which is equivalent to ~34% of < 40 years CRC patients 
amongst all CRC patients. This figure is of the same order as the values from several Asian and 
African countries cited above. They are also substantially larger than values recorded in 
National Cancer Registry (PBCR) in four Indian metropolises. The PBCR ratio is 0. 20 and has 
remained stable over 16 years (1988-2004).  
The difference between PBCR values and those reported by five premier hospitals in 
India, irrespective of their location and specialty, cited by Gupta et. al. (2010) has a clear 
message. The concern and facilities for cancer detection in the premier hospitals is greater 
than those in district hospitals. The data of the district hospitals are reflected in the PBCR 
values. This is the reason for the larger proportion of under-40 patients reported by the 
premier hospitals. The reason for delay in diagnosis of a young patient in either the 
premier hospitals or the district hospitals, particularly in the developing world, is that 
unless there is a family history these patients are not screened. So cancers are usually 
symptomatic at presentation. Even when symptoms occur, they may initially be 
misdiagnosed. Rectal bleeding for example is often put down to an anorectal cause. 
O’Connell et. al. (2004a) report an average delay in diagnosis of 6. 2 months, the reasons 
for which include a delay in presentation on the part of the patients, limited access to care 
and misdiagnosis on the part of the physician. This delay is larger in the developing 
world. Minimizing delay in diagnosis means not taking such symptoms lightly. Rectal 
bleeding usually has an anorectal cause, but when no such cause is obvious and the 
bleeding persists, colonoscopy is mandatory, regardless of patient’s age. The same 
concern must apply to other less obvious symptoms.  
In a review on CRC in Asia, Sung et. al. (2005) placed India at the bottom of the list amongst 
Asian countries, in order of decreasing CRC incidence. The data we provide does not 
contradict this assessment, but if relative incidence in the young is an indication, India has 
joined the rest of Asia.  
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3. Disease stage and tumour characteristics in the young adults 
The most powerful predictor of outcome for young adults, as it is for older patients is 
disease stage. Two staging systems are in use and are cited in Table 1-3. One is the tumour-
node-metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC). 
Microscopic extent of tumour invasion (T stage) and nodal involvement (N stage) from 
histological assessment are combined with assessment for metastatic disease (M stage) to 
specify a tumour stage. Brief description of TNM stages are: Tumour stages (T): Tumour in 
T1, invades submucosa, T2: invades muscularis propria, T3 and T4 are more extensive, T3 
indicates invasion through muscularis propria into subserosa or into nonperitonealised 
pericolic or perirectal tissues while T-4 invades adjacent organs. Regional Lymph node 
stages: N1: 1-3 positive nodes, N2:4 or more positive nodes. Distant metastases stages (M): 
M1: Distant metastases present. The other classification system known as Dukes’ system is: 
A: limited to bowel wall, B: penetration of bowel wall, C: lymph node involvement, D: 
distant metastatic disease present (Fry et. al. 2008). 
Mucinous adenocarcinoma is one of the histological subtypes of colorectal cancers. It 
accounts for 5-15% of all primary CRC and is defined as a tumour with >50% of its body 
showing a mucinous pattern on histological examination and with a large amount of extra 
cellular mucin produced by secreting acini. This is distinct from signet ring adenocarcinoma, 
a rare variant in which mucin remains inside the cell, which is well known for its 
aggressiveness. It has been suggested that mucinous adenocarcinoma behaves differently 
from more common histological subtypes of CRC. However, its clinical implications remain 
unclear. According to published series, mucinous adenocarcinoma affects younger patients, 
is more frequent in proximal part of the colon and tends to present at a more advanced stage 
(Negri et. al. 2005).  
In Table 1, 2 and 3 we tabulate data on disease stage and tumour characteristics, in 
particular its mucinous nature, of CRC patients in the USA (Table 1), in Europe, inclusive of 
Turkey and the UK and Australia (Table 2) and in Asia and Africa (Table 3).  
Several reports cited in Table 1 (Sr No 1,2,3,5,7,9,14) were entirely on features of CRC in 
the younger patients. In several other reports (Sr No. 4,6,8,10-13,15), both the younger  
and the older patient groups were studied and comparative features were assessed. The 
size of the younger group was mostly ~50, was ~200 in two reports (Sr No 3 and 4) and 
was 1025 in the work of Dozois et. al. (2005) (Sr no 14), the largest cohort of young CRC 
patients. In reports that included older and younger patients, older patients were much 
larger in number (Sr No 4,8-10). In all studies that were on younger patients alone, a high 
incidence of advanced stage (C+D: >70%)was reported. In studies that included both 
groups, the frequency of advanced disease in the young was as high or higher (Sr No. 
4,11,15). In all of them, advanced disease stages were found to be more frequent in the 
young than in the old. In studies on younger patients alone, a significant proportion of 
patients had aggressive lesions, namely mucinous, poorly differentiated tumours with 
infiltrating leading edge. The frequency of aggressive tumour biology varied  
from one study to another but remained significant in all of them. In the comparative 
studies  (Sr No. 6,8,10-12,15), the younger patients showed a higher frequency of 
aggressive tumour biology. Only one report (Sr No. 13) concluded that grade was not 
related to age.  
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Country  
Sr 
No.  
Reference, 
Period of 
study 
Age profile Disease stage 
Tumour 
characteristics 
France 1 
Adloff 
1973-1980 
1037 
patients; 3% 
<40yrs 
No significant 
difference in stage 
between <40 and >40 
Yrs group.  
Greater frequency 
of mucinous and 
poorly 
differentiated 
carcinoma 
in the  
young 
Finland 2 
Jarvinen 
1970-1979 
249 patients, 
<40yrs 
53% Dukes’ C and D.  
Premalignant 
condition  
more common in 
young 
Greece 3 
Frizis 
1994-2003 
Two 
groups: 11 
young 
<40yrs; 45 
old > 80 yrs.  
Dukes’ C 54. 5% in the 
young and 44. 4% in 
the elderly group.  
Undifferentiated 
tumour:  
36. 3% 
 of the young and 
8. 8% 
of elderly. 
Sweden 4 
Ohman  
1950-1979 
48/1061 
patients are 
<40 years 
(21-39 
years) 
Dukes’ A same 
proportion in young 
and old,  
Dukes’ B fewer, 
Dukes’ C more  
in young 
 
Norway 
5 
Endreseth 
1993-1999 
2283 
patients 
with rectal 
cancer <70 
years, 
<45 yrs: 132, 
45-49 yrs: 
153 
50-69 
yrs:1998 
Dukes’ C&D : 
under 45: 
73/132(~55%) 
45-69yrs: 
998/2152(~46%) 
Higher frequency 
of poorly 
differentiated 
tumours 
(27 vs. 15%) & N-2 
stage (37 vs. 15%) 
with distant 
metastases (38 vs. 
20%); 
56% of under-40 
years: developed 
metastases 
(20-26% of older 
group)  
after tumour 
resection 
6 
Berg 
2010 
181 patients, 
45 of them < 
50 yrs 
Dukes’ C &D 
54% in < 50 yrs group 
46% in 51-70 yrs 
36% in > 70 yrs 
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Country  
Sr 
No.  
Reference, 
Period of 
study 
Age profile Disease stage 
Tumour 
characteristics 
UK 7 
Leff 
1982-1992 
49 patients 
all 
< 40 yrs: 
67% in 31-40 
yrs, 2 in 
their teens 
Among all patients: 
60% Dukes’ C&D.  
Among patients at 
risk (family history 
/predisposing factor): 
56% Dukes’ C 
Among all patients: 
59% moderately & 
22% poorly 
differentiated . 
Among patients at 
risk: 53% 
moderately & 20% 
poorly 
differentiated 
Italy 8 
Fante 
1984-1992 
Three 
groups <40, 
41-50, 
51-55 years: 
~1%, 6%, 
6% of 1298 
patients 
Stage did not differ 
Histological 
features did not 
differ 
Turkey 9 
Yilmazlar 
1986-1993 
237 patients; 
46 below 
40yrs 
76%of the young: 
Dukes C&D 
48% tumours are 
poorly 
differentiated or 
mucinous in 
young. 
Australia 10 
Turkiewitz 
1971-1999 
61/2384 
below 40 
years 
Distribution of stage 
not significantly 
different in  
younger and older 
group 
35%tumours in the 
young are poorly 
differentiated 
Table 2. Summary of references in the literature on stage and tumour characteristics from 
Europe (inclusive of UK & Turkey) and Australia  
Two of the reports from Europe listed in Table 2 (Sr.No.2,7) are entirely on young 
patients. One of these ( Sr No. 2) has the largest study group of young onset patients 
(~250), while the other reports have ~100-150 (Sr Nos. 5,6,8) or less ~50 (Sr No. 
1,4,7,10)young patients. The report, Sr No. 3 is on a much smaller population of 11 
patients. A significant frequency of more advanced (C+D) tumour in the young (50-60%) 
was reported in several studies (Sr No. 2,3,5-7). This frequency was larger (76%) in a study 
from Turkey (Sr No. 9). Comparative assessment showed a higher frequency of advanced 
stages in the young as compared to that in the older patients (Sr No. 3-6). Significant 
frequency (~ ≤50%) of high grade tumours were reported in the young in several 
publications (Sr Nos. 3,5,7,9,10). Higher frequency of high grade tumours in the young as 
compared to the older group were cited in several other papers (Sr No. 1,3,5,7). Three 
studies (Sr No. 1,8,10) however, reported no difference in disease stage and one report (Sr 
No. 8) found no difference in tumour grade, between the younger and older patient 
groups. A significant occurrence of premalignant conditions in the young was reported in 
only one paper (Sr No. 2).  
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Country 
Sr 
No 
Reference, 
Period of 
Study 
Age profile Disease Stage 
Tumour 
Characteristics 
ASIA 
Iran 
1 
Fazeli 
1995-2001 
403 patients in 
two age 
groups, 
<40yrs and 
>40yrs 
Older group:  
53. 2% in stage II;  
younger group: 
 45%in stage III.  
Poorly 
differentiated 
tumours  
found in larger 
proportion in 
younger 
patients  
(22% vs. 5. 9%) 
Singapore 
2 
Kam 
1989-2001 
39 patients 
<30yrs, 
mean age 25yrs 
Advanced disease 
stage in 70% patients.  
Mucinous 
histology: 
18%; 
differentiation: 
moderate  
61%,  
poor 36% 
3 
Chew 
1997-2005 
523 Asian 
cohorts  
19-50 years 
Of them  
<40 yrs:134; 
>40yrs:389 
63% Advanced stage 
(III-IV) 
<40yr group: 
89/134;66% 
>40yr group: 
245/389;63% 
Predominantly 
poorly 
differentiated: 
(30% in <40 
years 12%  
in > 40 years) 
mucinous, 
signet  
ring cell 
histological 
subtypes  
(16% vs. 9%). 
Malaysia 4 
Shahruddin 
1990-94 
21 patients 
<30yrs 
Extensive disease 
Mucinous 
histology 
Israel 
5 
Shemesh-
Bar,  
1997-2007 
406 patients, 
203 in < 50 
years 
More advanced  
stage III-IV at 
diagnosis  
(56 vs. 41%)  
higher rate of N-2 
disease  
(29 vs. 16%) 
No difference in 
other features 
6 
Neufeld 
1999-2005 
<50 years 90; 
190 > 50 years 
40%  
Advanced stage  
(III-IV) 
<40yrs:47/90;52% 
>40yrs:61/190;32% 
Mucinous 
tumour in  
11% in  
early onset 
group,  
7% in late onset 
group 
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Country 
Sr 
No 
Reference, 
Period of 
Study 
Age profile Disease Stage 
Tumour 
Characteristics 
Taiwan 7 
Chiang 
7 year period 
5436 patients 
7% <40 years 
Dukes’ stage 
improves with age  
(A & B 31%  
< 30 years,  
49% > 80 years) 
Poorly 
differentiated 
tumours tended 
to decrease with 
age,  
16. 9% < 30 
years. 
6. 2% > 80 
years.  
Similar trend in 
Mucin 
producing 
characteristics 
(36% vs7. 5%) 
India 
8 
Nath 
2003-2007 
287 patients 
35. 6% < 40 yrs 
Advanced T stage 
(T 0-2: 18. 9% 
T -3: 62. 3% T-4: 19. 
7% vs. 34. 5%, 56. 0%, 
9. 5%) and N-stage (N 
0: 31. 1%, N1: 41%, 
N2: 27. 8% vs. 53. 9%, 
26. 7%, 17. 2% ) 
Poorly 
differentiated 
and / or 
mucinous or 
signet cell 
carcinoma  
(52% vs. 20. 5%) 
9 
Gupta 
2000-2008 
305 patients 
40% < 40 yrs 
60% presented in 
Dukes’ stage III & IV 
Mucinous 
tumour  
80% 
Poor 
differentiation 
50% 
Nepal 10 
Singh 
2002a 
91 patients 
28. 6% < 40 yrs 
92. 3% present in 
Dukes’ stage III-IV vs. 
61. 5% in older 
patients 
Significantly 
higher  
poorly 
differentiated 
and mucinous 
carcinoma  
in the  
young. 
SriLanka 11 
de Silva 
15 yr period 
305 patients 
19. 7% < 40 yrs 
No significant 
difference in Dukes’ 
stage with older 
group 
Significant 
presence  
of mucinous  
(13. 3%) or 
signet  
ring type  
(5%) tumours. 
www.intechopen.com
 
Colorectal Cancer – From Prevention to Patient Care 
 
22
Country 
Sr 
No 
Reference, 
Period of 
Study 
Age profile Disease Stage 
Tumour 
Characteristics 
AFRICA 
Egypt 
12 
Soliman* 
1982-1996 
1608 patients; 
35. 6% <40 yrs 
Dukes’ stage is  
worse in 
> 40 years group  
(72% vs. 57%) 
Tumour grade 
comparable in 
two groups; 
mucin 
producing 
tumours: 31% 
in younger 
group, 14% in 
older group 
*Soliman et. al. (1997) 
Table 3. Summary of references in the literature on stage and tumour characteristics from 
Asia and Africa. 
Reports from Asia and Africa are listed in Table 3. Features of only the younger patients 
were assessed in four reports (Sr. No. 2-4,9). The younger groups were larger in several 
studies (523:Sr No. 3; 203:Sr No 5; 370: Sr No. 7and 576 : Sr No. 12) from Asia and Africa 
as compared to ones from the USA (Table 1) and Europe (Table 2). Higher incidence of 
CRC in the young in Asia and Africa was found to be consistent with these figures. In two 
studies (Sr No. 11,12) the disease in the young was assessed as less advanced at 
presentation and less aggressive. In one report (Sr No. 5),a more advanced disease stage 
was noted but no difference in tumour grade was found. A more advanced disease and 
tumour grade was reported in the young as compared to the older patients (which is 
usually the case in Table 1 & 2) in 5 of 12 reports (Sr No. 1,6-8,10). In a report by Chew et. 
al (2009, Sr No. 3) the same conclusion was reached; ‘older’ patients were however in the 
age group 40-50years. The frequency of advanced disease and high tumour grade in the 
young in these reports were similar to that in reports restricted to only the young patients 
(Sr No. 2,4,9).  
Irrespective of the country, the size of the study group, time span and the year of study, 
the dominant result is the same. Young CRC patients present at a more advanced clinical 
stage, the tumours are mucinous and poorly differentiated, more so in comparison with 
the older patient group. The features in India and neighbouring Nepal and Sri Lanka are 
the same as in the rest of the world. We have noticed some difference in disease pattern in 
Asia and Africa as compared to the West in our discussions of the data in Tables 1-3. The 
issue of ethnic differences in determining the difference in disease characteristics is 
important. This issue, without specific reference to the disease in the young, received 
attention in several papers, e. g., Isbister (1992; New Zealand and Saudi Arabia), Soliman 
et. al. (2001; Egypt and the West), Fireman et. al. (2001;Arab and Jewish neighbours in 
Israel),Qing et. al. (2003;USA and China), Sung et. al. (2005;Asia and the West),Goh et. al. 
(2005;Asian patients of different races in Malaysia) and Fairley et. al. 
(2006;Blacks,Asians/Pacific Islanders and Whites).  
The advanced stage at presentation of many colorectal cancers in young patients is not just a 
result of a delay in diagnosis. It may also be that the cancer in younger patients is more 
virulent by nature. This feature is rooted in subtleties of genetic differences. More 
aggressive’ tumour characteristics, as evidenced by its mucinous nature and poor 
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differentiation have also been linked to molecular genetic differences. Recent molecular 
biology studies have shown characteristic features of mucinous carcinoma, e. g., lower 
expression of p53, more frequent DNA replication errors expressed  as microsatellite 
instability and specific codon 12 K-ras mutations and, when ploidy has been determined, a 
higher index if diploidy was found than for non-mucinous carcinoma (Negri 2005).  
Tumour subsite: The issue of subsite location is important in screening strategies and in 
choice of treatment protocols. In the literature (e. g. , Breivik et. al. 1997) preference for 
subsite location has been associated with molecular genetic roots of CRC. Molecular genetic 
findings classify CRC into two groups. The first class of tumours show microsatellite 
instability (MSI), occur more frequently in the right colon, have diploid DNA, behave 
indolently, of which Hereditary Non polyposis Colorectal Cancer Syndrome (HNPCC) is an 
example. The larger incidence of proximal colon cancer in patients with HNPCC syndrome 
highlights the importance of genetics in preference for subsite location in colon cancer. In 
the other group belong tumours which tend to be left sided, show aneuploid DNA, behave 
aggressively, of which Familial Adenomatous Polyposis (FAP) is an example. Each group 
has its own characteristic gene mutations (Lynch and de la Chapelle, 1999).  
Breivik et. al. (1997)in a study of 282 patients from 7 hospitals in Norway in the period 1987-
9 concluded that proximal and distal CRC evolve by different genetic pathways and that 
these pathways are influenced by sex-related factors. Their results, analyzed by statistical 
models, pointed to hormonal mechanisms with important clinical implications. They found 
that presence of TP 53 mutations was dependent on tumour location only, with a positive 
association to cancers occurring distally (p=0. 002). Microsatellite instability was found 
almost exclusively in proximal colon cancers.  
Stigliano et. al. (2008) compared a cohort of 40 HNPCC cases with 573 sporadic CRC cases in 
the period 1970-1993. Median age of diagnosis was 46. 8 years in HNPCC cases and 61 years 
in sporadic CRC cases. 85% had right sided lesion in HNPCC group as opposed to 57% in 
sporadic cancer group.  
Slattery et. al. (1996) studied age, sex and tumour sub-site distribution in 1709 CRC patients 
from three geographic areas in the USA. Approximately 50% of CRC in men and greater than 
50% of CRC in women were in the proximal segment of the colon. Men who were diagnosed 
prior to age 50 and both men and women diagnosed at age 70 or older had predominantly 
proximal cancers. People with proximal cancers and those diagnosed prior to age 50 were  
likely to have more advanced disease. In general, both men and women had more proximal 
cancers with advancing age, which were associated with more advanced disease.  
Ionov et. al. (1993) showed that 12% of CRC patients carried ubiquitous somatic deletions in 
poly (dA. dT) sequences and other simple repeats. Tumours with these mutations showed 
distinctive genotypic and phenotypic features. Patients with these deletions showed a 
predominance of right sided tumours while those without deletions had a predominance of 
left sided lesions.  
Thibodeau et. al. (1993)studied the association of microsatellite alterations with preference 
for tumour subsite. All four sites of alteration studied showed a dramatic change in 
preference from distal to proximal colon in the mutated form (typical values: 
proximal/distal; (26,49), (11,1 in the mutated form)).  
Fancher et. al. (2011) studied 45 young patients, 20 males and 25 females,mean age 43. 6 
years, in the USA and found preference for left sided lesions in females (16/8)and a 
preference for right sided lesions (12/10)in men (p=0. 35; small sample size);right sided 
cancers had a higher stage at presentation.  
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Kaw et. al. (2002) studied 1277 Filipino patients of whom 218 (17%)were <40 years, a mean 
age of 31. 3 years. Cancers of the right colon were noted to be more common in females 
(55%)and rectal tumours were seen more frequently in males (55%;p=0. 014),but when 
analysed in relation to age, right colon cancers were actually more common in men <40 
years of age (p=0. 013);the incidence in women was higher only above the age of 50 years. 
The proportion of CRCs located on the right side was 28% for <40 years patients and 20% 
for the 40+ group. On the other hand, left colon cancers were seen in 30% of the older age 
group compared with 18% in the younger population (p=0. 001). For rectal cancer, there was 
no significant difference in proportion between the young and the old (p=0. 414).  
Elsaleh et. al. (2000) in an older patient group (mean age 66. 7 ±12. 9 years) in Australia 
reported that MSI positive tumours were slightly more frequent in women than in men (10 
vs 7%). Right sided tumours were more frequently MSI positive than left sided tumours (20 
vs 1%). Men with right sided tumours benefited from chemotherapy (37 vs 12%) but men 
with left sided tumours did not.  
Mahdavinia et. al. (2005), Fazeli et. al. (2007) and Malekzadeh et. al (2009) found that in 
Iranian patients with positive family history of CRC, the most frequently affected site of 
colon was the right side. Malekzadeh et. al. (2009) found that MSI was more frequent in 
early-onset patients and in proximal tumours. They reported that proximal and distal 
tumours harbor different p53 mutational spectra;distal CRCs showed a higher frequency of 
G to A transitions at CpG whereas G to A transitions at non-CpGs were more frequent in 
proximal tumours. Fazeli et. al. (2007) found that 62. 5% of patients with proximal colon 
tumours were males.  
Nelson et. al. (1997) and Saltzstein et. al. (1997) showed that there was an increase in the 
relative proportion of proximal colon cancers with increasing age ‘a shift to the right’. Thus 
with increasing age, full length colonoscopy will be a better screening tool. The exact age at 
which the shift occurs will vary with gender and ethnicity. There is a predominance of 
African-Americans amongst those at risk for proximal colon carcinoma and predominance 
of white males amongst those at risk for distal CRC.  
Goh et. al. (2005) in a study of different races in Malaysia observed that demographic 
differences between Asia and the West may exist. No difference in anatomic distribution 
was found in Malay, Chinese and Indian races. They noted that in general CRC tends to be 
located distally in areas with a lower incidence of disease (parts of Asia) and migrated 
proximally with increasing incidence, as in Japan or Korea. They suggested that this may be 
related to a decrease in rectal cancer and an increasing proportion of elderly patients in the 
population. Young patients had a higher probability of having distal lesions as compared to 
the older patients.  
Qing et. al. (2003) in a comparative study on Chinese and American patients, noted that the 
proportion of left sided lesions in Oriental patients (74%) was significantly higher than that 
in Whites (63. 7%) and that rectal cancers were significantly more common among Orientals 
(p<0. 001).  
O’Connell et. al. (2004a) in their review quoted average values of subsite location in <40 
years young patients as follows: ascending 22%, transverse 11%, descending colon 13%, 
rectum and sigmoid (including rectosigmoid junction) 54%,a dominance of left sided 
tumour in the young.  
We summarize reports on preference for tumour sub-site from different countries in Table 4. 
Some of these are cited in Table 1-3 where patient groups are detailed. The others are 
detailed in Table 4.  
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Asia & 
Africa 
Sr. 
No. 
Author, Country Sub-site 
1 Gupta, India 
69. 7% distal tumours in < 40 yr group  
(rectal 57. 9%,left colon 11. 8%).  
Of patients with colon cancer proximal tumours 
constitute 72%.  
2 Singh, South Asia* 
Rectum: commonest (83%) site of the lesion in 
young patients (21-30 yrs). No comparison with 
older patient group.  
3 Singh, Nepal 
Rectum: most frequent site of tumor  
(76. 9% vs. 36. 9% in older age group)  
4 de Silva, Sri Lanka 
No significant difference in tumour  
distribution between the young  
and the old.  
5 
Shahruddin, 
Malaysia 
Rectosigmoid region:most common (29%)’  
Left colon 19%,Splenic flexure 4%,Transverse 
colon 9%,Hepatic flexure 4%, 
Cecum 24% ;all patients<30yrs 
6 
Goh, Asian patients 
of different races in 
Malaysia 
 No significant difference between <and >  
65 years group; predominance  
(~90%)of left sided lesion in both age groups.  
7 Kam, Singapore 
46% rectal and rectosigmoid; right-sided 
tumour:20%; 
patient group, all young <30yrs 
8 Ashenafi, Ethiopia 
66. 7%rectal lesions; younger patients;  
mean age 47 years  
(61. 4% <50years, 36% <40 yrs,16% <30 yrs) 
9 Shemesh-Bar, Israel 
Higher proportion of left side tumour in the 
young (82% vs. 71%) 
10 
Chew, Singapore 
(Asian patients) 
Predominantly left sided tumour (~80%)in <40 
years and 41-50 years age group;  
no effect of age.  
11 Malekzadeh, Iran 
Predominantly right sided tumour,  
general population 
12 Ibrahim, Lebanon 
Rectosigmoid most common site in general 
population (553 patients),70. 7%;also in 32,<29 
years younger group: 84. 4% 
13 Fazeli , Iran 
Subsite distribution nearly independent  
of age group (< & > 40 years),  
distal ~ 80% in both groups.  
14 Chiang, Taiwan 
No change in subsite preference from < 30 years to 
> 80 years 
15 Soliman**, Egypt 
No change in subsite preference in < 40 years  
vs. > 40 years group,  
larger proportion of distal tumours  
(~65%) in both age groups 
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U. S. A.  
Sr. 
No. 
Author, Country Sub-site 
16 Bedekian, USA 
Increase in primary lesions in the right colon with 
increasing age at diagnosis; <40 yrs group 
compared with general population.  
17 Cozart, USA 
Dominance of left sided lesions  
(12 right colon, 24 left colon,11 rectum)  and left 
colon amongst colon cancer patients; study group 
comprises of only young patients<30yrs. No 
comparison with older group.  
18 
Nelson, USA & 
Saltzstein, USA 
Significant shift to right sided lesion with 
increasing age;<50 vs. >50yrs.  
19 Slattery, USA 
Proximal cancers more frequent (>50%) in men<50 
years and in both men and women >70 
years(details in text).  
20 Fairley, USA 
Rectal cancers more frequent in <50yrs group 
(37% vs. 26%); proximal colon cancer more 
frequent in >50 age group (42. 6% vs. 32. 
1%),remaining <50%in both groups.  
21 Lichtman, USA 
Older patients: more transverse/right sided 
lesions (p=0. 003). 138 patients;mean age of 
patients with different sites of tumour: 
Right colon 72 yrs,left colon 66. 1 yrs,  
rectum 61. 6 yrs 
22 Karsten, USA 
Right sided lesion more frequent (44%)in young 
compared to 21% in older group, p=0. 004.  
23 Minardi, USA 
Tumours evenly distributed in colon and rectum 
(under-40 group).  
Older group not compared.  
24 
O'Connella 
(International Review) 
Rectum and sigmoid colon most frequent sites 
(54%) in the young <40 yrs patient group.  
25 Dozois, USA 
Predominantly rectum (49. 1%) or left colon  
(29. 1%) than proximal colon (21. 9%).  
All young patients <50yrs.  
No comparison with older patient group.  
26 Behbehani, USA 
Colon: Right 21%,Transverse 21%, Left 14%  
Sigmoid & Rectum 44% in the <40 yrs group; these 
figures are 34%,4%,8%,54% respectively in the 
older group.  
Europe 
27 Leff, UK 
Only 12% right-sided colon cancer,<40 yrs 
patients, no comparison with older group.  
28 Fante, Italy 
Majority of tumours in left colon and rectum in the 
whole patient group <40 – 55 years.  
Right colon: 37% in <40 years, 18% in 41-50 years, 
14% in 51-55 years group.  
*Singh et. al. 1984; **Soliman et. al. (1997) 
Table 4. Tumour Sub-site in the young in different countries 
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In some of these papers, (Sr. No. 1, 2, 5, 7, 8, 10, 17, 23-25, 27), a preference for distal lesions 
in the young patients were cited, but were not compared with the older patient groups. In 
some others (Sr. No. 3, 9, 12, 16, 18-21) this comparison was made and a change in 
preference for tumour sub-site with increasing age was noticed. Shemesh-Bar et.al. (2010, Sr. 
No. 9) and Ibrahim et. al. (1986, Sr. No. 12) found that although left sided lesions formed the 
majority of tumours, their proportion decreased in the older group. Singh et. al (2002a, Sr. 
No. 3) and Fairley et. al. (2006, Sr. No. 20)found that the proportion of rectal cancers 
decreased with increasing age. In several reports preference for right sided lesions showed 
an increase with increasing age (Sr. No. 16, 18, 20-21). Slattery et. al. (1996, Sr. No. 
19)reported an increase in proportion of proximal tumours with increasing age for women, 
exceeding 50% (62. 3%), only in the age group 70-79 years. Amongst men, proportion of 
proximal tumours exceeded 50%in the <50 yr groups (62. 5%, 30-39 yrs; 51. 1%, 40-49 yrs), 
falls below 50%in the 50-59 and 60-69 yrs groups and then rises again to 54% in the 70-79 yrs 
group. A decrease in proximal tumours with increasing age was reported by Karsten et. al. 
(2008, Sr. No. 22) and Fante et. al. (1997, Sr. No. 28). Both studies reported a dominance of 
distal tumours in different age groups (two in Sr. No. 22, three in Sr. No. 28), but proximal 
tumours decreased with increasing age. In a few papers (Sr. No 4, 6, 10, 13-15, 26) sub-site 
preference was found not to depend on age. Fazeli et.al. (2007, Sr. No. 13) reported that~ 
80% of the tumours were distal in the young (<40 years) and also in the older age group. In 
these reports which did not find any effect of age on subsite preference, distal tumours were 
>50% in the young and in the older group. A preference for proximal tumours in a 
population of colon cancer patients were reported in several papers (Sr. No. 11 and 
Mahdavinia et. al. (2005) in general population of colon cancer patients from Iran, where 
incidence is lower than in the West and in Sr. No. 1 in young colon cancer patients < 40 
years in India). Cozart et. al. (1993, Sr. No. 17) found tumour sub-site preference for left 
colon (24/12) in a small population of colon cancer patients; Dozois et. al. (2005, Sr. No 25) 
found the same preference in a much larger (1025 patients) young (<50yrs)population. We 
cite several prospective reports on change in relative preference of tumour sub-site over a 
long time period. Fazeli et. al. (2007, Sr. No. 13) reported that the nearly equal preference for 
distal tumours (~80%) in the <40 years and in the >40 years group in Iran, remained 
unchanged for two decades (1970-80, 1990-2000). In contrast, it was reported in a study on 
patients from New Zealand, in the period 1974-83 (Jass 1991), that the incidence of right 
colon cancers remained stable in younger patients (<50 years), that in older patients showed 
an increase and a marked reduction in left colon and rectal colon cancer in <50 years group 
was observed. An increase in proximal CRC relative to distal tumours was reported in 
another retrospective study in the period 1940-79 in the US (Beart et. al. 1983).  
4. de novo CRC in Asia 
The problem arising from inability to detect cancer early because of hospital infrastructure 
and relative lack of awareness of the disease may not be the only problem peculiar to the 
developing world in Asia and Africa. Sung et. al. (2005) pointed out that non-polypoidal 
(flat or depressed) lesions and colorectal neoplasm arising without preceding adenoma (de 
novo cancer) seemed to be more common in Asian than in other populations. Although 
most cases of colorectal cancer are thought to arise from a sequence of adenoma to 
carcinoma, evidence from Asia, in particular Japan suggests another mechanism. 
Clinicopathological studies have shown that there are two groups of colorectal cancer, 
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polypoid and non-polypoid (superficial) tumours. The latter are flat lesions with a raised or 
depressed surface. Since these tumours are small (<1cm in diameter) and there are no 
adenomatous elements in their vicinity, they were proposed not to have originated from any 
precursor lesion and were termed de-novo carcinomas. These non-polypoid tumours are 
less likely to have K-ras mutations than are CRC arising from the adenoma-carcinoma 
sequence. Non-polypoid tumours of the colorectal regions tend to reach deeper layers of the 
intestinal wall in the early stage of the disease and with a higher degree of dysplasia. They 
are therefore more invasive than the polypoid adenomas (Sung et. al., 2005). Reports on de 
novo cancer have been published from Japan (Goto et. al 2004) and from Taiwan (Chen et. al 
2003). About one-third of CRC patients in both countries have de-novo cancer. One study 
from UK also reported this feature (Rembacken et. al., 2000). Whether this feature is unique 
to Asia or whether it shows any preference for the younger or the older group of patients is 
not reported. Because of their flat appearance they are harder to identify by conventional 
colonoscopy. Chromoendoscopy and the use of magnifying colonoscopy may be necessary. 
The absence of polypoid growth preceding malignancy has posed difficulties in screening 
for early CRC by radiological imaging or even endoscopic techniques.  
5. Early onset CRC and genetics 
Colorectal tumours provide an excellent model system for understanding the molecular 
events that control the process of initiation and progression of human tumours. Rate of 
random mutational events alone cannot account for the number of genetic alterations found 
in most human cancers and it has been suggested that destabilization of the genome may be 
a prerequisite early in carcinogenesis. In CRC there are two separate destabilizing pathways. 
The more common involves chromosomal instability (CNI). The second mutational pathway 
in CRC displays increased rate of intragenic mutation characterized by generalized 
instability in microsatellites (MSI). Defects in mismatch repair genes (MMR) lead to high 
frequency MSI in CRC. National Cancer Institute definitions of MSI-L (L=low), MSI-H 
(H=high) and MSS (microsatellite stable) in CRC are given in Boland et. al. (1998). A recently 
recognized molecular alteration found frequently in MSI cancers is the CpG island 
methylator phenotype (CIMP). Colon cancer is usually observed in one of three specific 
patterns: sporadic, inherited or familial. Fewer than 10% of patients have an inherited 
predisposition to colon cancer. Sporadic cancer is common in persons older than 50 years of 
age, probably as a result of dietary and environmental factors as well as normal aging. 
Patients with inherited disease have CRC at a younger age, 10-20 years earlier than general 
population and are of interest in this essay. The area of hereditary CRC has been reviewed 
by Lynch and de la Chapelle (2003)and earlier by Lynch et. al (1991). Different aspects of 
molecular genetics of CRC have been discussed in this series (Ewart Toland, 2012) and 
elsewhere (Fearon and Volgenstein 1990; Loeb 1994; Jass 1995; Lynch 1996; Baba 1997; Gryfe 
et. al. 1997; Lengauer et. al. 1998; Lynch and Smyrk 1998; Lynch and de la Chapelle 1999; 
Yang 1999; Potter 1999; Jass et. al. 2002; Calvert and Frucht 2002; Zbuk 2009). In this section 
we discuss several recent papers which highlight the difference in genetic characteristics of 
younger CRC patients and those of the older group.  
Morris et. al. (2007) showed that the incidence of tumours with microsattelite instability was 
significantly higher in patients aged  40 years, 18. 3% compared to 6. 6% in those aged 41 – 
60 yrs (p<0. 0001). TP53 mutations were also more frequent (p=0. 002). However K-ras 
mutations were less common (p=0. 0001) when comparing the same age groups. They 
www.intechopen.com
 
Colorectal Carcinoma in the Young 
 
29 
concluded that major age related differences in the clinical and molecular features of CRC 
exist.  
Farrington et. al. (1998) pointed out that germ-line mutations in DNA mismatch-repair 
(MMR) genes impart a markedly elevated cancer risk, often presenting as autosomal 
dominant HNPCC. Not all gene carriers have a family history. Young probands with early 
onset CRC irrespective of family history were genetically tested and it was found that an 
appreciable proportion of young colon cancer probands carry a germline mutation in a 
DNA MMR gene.  
Losi et. al. (2005) evaluated clinical features and molecular pathways, chromosomal 
instability (CNI) and MSI in early onset CRC. Of 71 patients (<45 years), 14 showed both 
MSI and altered expressions of MMR proteins. In the 57 MSI -negative (-) lesions, altered 
expression of APC, β-catenin and p53 genes were found more frequently than in MSI-
positive (+) tumours. 7/14 MSI (+) tumours were associated with clinical features of 
HNPCC and in all but one, constitutional mutations in MLH-1 and MSH-2 genes could be 
detected. The same mutations were found in other family members. Involvement of 
chromosomal instability was demonstrated in a majority of early onset CRC.  
Chan et. al. (1999)studied 59 Chinese patients <45 yrs and 58, >45 yrs in Hong Kong. The 
incidence of MSI-H varied statistically significantly with age, being observed in >60% of 
those <31 years at diagnosis and in <15% of those ≥46 years. More than 80% of Chinese CRC 
patients <31 years had germline mutations in MMR genes. In a novel case, mutation in 
hMSH-6 was present but MSI was absent.  
Ho et. al. (2000) in a study on 124 young (<50yrs) Hong Kong Chinese CRC patients 
concluded that MSI occurs in a significant proportion of the subjects. Young age at CRC 
diagnosis, proximal tumour location, increasing number of first degree relatives with CRC 
and a personal history of metachronous cancer were independent predictors of MSI status in 
the patient group. In patients <30 years, MSI tumours were more likely to be located in 
distal large bowel. In a proportion of patients with MSI tumours, germline mutation in the 
two MMR genes hMSH2 and hMLH1 was identified. The authors opined that this 
observation suggests a differential activity of the MMR pathway in colorectal carcinogenesis 
in different age groups. They observed that the inconsistency between MSI-H and a family 
history in the early onset patients deserves further attention.  
Liang et. al. (2003) studied 138 below-40 CRC patients and 339 patients who were 60+. They 
found a higher percentage of normal p53 expression (61. 1 vs. 46. 8%, p=0. 023) and high 
frequency microsatellite instability (MSI-H) ( 29. 4 vs. 6. 3% p<0. 001) in the young. The 
family history of the two groups was similar.  
Durno et. al. (2005, 2006) found evidence of MSI in 73% cancers from individuals in 9-24 
years of age, 50% of whom had features of HNPCC. Other reports found MSI in 46% of 
under- 21 patients with only 1/3 having a clear family history.  
Sanchez et. al. (2009) performed a molecular classification of CRC based on microsattellite 
instability (MSI), CpG-island methylator phenotype (CIMP) and mutations in the K-ras and 
BRAF oncogenes. There were four classes, combinations of MSI-H and MSS  with CIMP–H 
or CIMP (-). 69. 8% of tumours (391 subjects) were MSS-CIMP(-) and less likely to be poorly 
differentiated (p=0. 009). CIMP-H tumours were more common in older patients (p<0. 001). 
MSI-H/CIMP-H tumours had a high frequency of BRAF mutation and a low rate of K-ras 
mutation, the opposite was true for MSS-CIMP(-) tumours (p<0. 001). The four molecular 
phenotypes tended towards divergent survival. MSI-H cancers were associated with better 
disease free survival.  
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Alsop et. al. (2006) investigated association of young age in below-45 patients with somatic 
mutation of K-ras gene, a common event in CRC tumorigenesis. The role of these mutations 
was found to be comparatively minor in the younger group, in contrast to its significant role 
in CRC of older age of onset.  
Soliman et. al. (2001) compared molecular pathology of CRC in Egyptian (44% <40 years) 
and Western patients. They found MSI-H carcinoma in 17% (2/12) of under-40 and 46% 
(12/26) of 40+ Egyptian patients; K-ras gene mutation in 0% (0/18) of under-40 group and 
in 17% (5/29) of 40+ group; p-53 overexpression in 57% (13/23) of under-40 group and 39% 
(13/33) of 40+ group. These data show that molecular pathology of CRC in young Egyptians 
differed from that in the old; in particular, K-ras mutation played a distinctly minor role in 
the younger group. Unique differences in molecular pathology of CRC between the 
Egyptian and Western patients were also discussed.  
Breivik et. al. (1997) found that the presence of K-ras mutation was dependent on age and 
gender of the patient, with an especially low frequency amongst young males. Microsatellite 
instability was rare in tumours with K-ras and TP53 mutations.  
Berg et. al. (2010) focused on the somatic tumour development in young patients with no 
known inherited syndromes. They studied mutations in oncogenes K-ras, BRAF, PIK3CA 
and the tumour suppressor gene PTEN and in TP53, in three age groups in 181 patients (45, 
< 50 yrs; 67, 51-70 yrs; 69, >70 yrs). Distinct genetic differences were found in tumours in the 
young and the elderly patients, who were comparable for known clinical and pathological 
variables. This result indicated that young patients had a different genetic risk profile for 
CRC development than older patients. Clinical implications of these differences were 
discussed by the authors. The total gene mutation index was lowest in tumours from the 
younger patients. In contrast the genome complexity assessed as copy number aberrations 
was highest in tumours from the youngest patients.  
Casper et. al. (1994) showed in a study on 225 FAP patients that deletion of 5 base pairs at 
codon 1309 within exon 15 (the most common mutation) was identified in 20 families. Other 
mutations within exons 7-15 were found in 49 families. The 1309 mutation leads to 
development of colonic polyps at a younger age thus giving rise to an earlier malignant 
transformation. In patients with 5 base pair deletion at codon 1309, gastrointestinal 
symptoms and death from CRC occurred about 10 years earlier than in patients with other 
mutations.  
Khan et. al. (2008) studied 35 patients with CRC diagnosed at <30 years age. They found no 
mutations in exons 4-10 of the p53 gene. The frequencies of polymorphism in p53 and in 
MDM2SNP309 did not differ from rates previously reported for normal control populations 
and no polymorphism in either gene could be associated with early onset CRC.  
Ahmed et. al. (2005) reported a study on 363 CRC patients of whom 18 were of Bangladeshi 
origin. 22% of Bangladeshi patients presented with a locally advanced or a metastatic CRC, 
whereas the same figure for non-Bangladeshi patients was 11%. Sixty one percent of the 
Bangladeshi patients were below 40 years of age and did not report any family history. 
Microarray profiling between these two groups demonstrated 1203 differentially expressed 
genes (p<0. 05). The patient groups studied by Nath et. al. (2005) and by our group, (Gupta 
et. al. 2010) (Table 3) and by Pal (2006) belong predominantly to West Bengal in India, which 
is adjacent to Bangladesh. These studies reported dominance of younger patients in their 
study groups, advanced disease stage and aggressive tumour characteristics.  
Liu et. al. (1995) studied the prevalence of DNA replication errors (RER) associated with 
genetic instability in relation to age among patients without HNPCC. RER was found in 
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cancers of several different types, particularly in HNPCC. CRC in majority of <35 years 
group (58% of 31 patients) exhibited instability whereas CRC in > 35 years group 
uncommonly did (12% of 158). In 12 of <35 years group, instability was evaluated for 
alterations of MMR genes and in 5, it was found to harbor germline mutations. These data 
suggested that the mechanisms underlying tumour development in young CRC patients 
differ from those in most older patients.  
Lin et. al. (2010) showed in a study cohort of 950 patients (2000-2005) that carcinogenic 
effects of Western lifestyle might be mediated via insulin-like growth factor-1 (IGF-1). IGF-1 
is a peptide growth factor that promotes cell proliferation and inhibits apoptosis. Both in 
vitro and in vivo studies suggested that IGF-1 could promote CRC growth. Further, 
circulating levels of IGF-1 were associated with various cancers including CRC. It was 
shown that genetic variation controls variability of circulating IGF-1. The expression of  
IGF-1 was reported to vary in different ethnicities. In turn it was speculated that 
polymorphisms of the genes involved in the IGF axis might affect IGF-1 expression and 
possible cancer risk. The age at onset of CRC varied considerably. Extreme age at the CRC 
onset, very young or very old seemed to be associated with different carcinogenesis. It was 
shown that some genetic polymorphism affects age of onset of cancers. For example IGF-1 
polymorphism plays a significant role in affecting disease onset in Lynch syndrome. These 
authors showed that older patients have a higher frequency of AA genotype of IGF-1 (-
2995C/A), significantly higher (12. 7%) than that in younger patients (4. 2%). Mucinous 
differentiation, but not other clinicopathological factors was associated with the CA /AA 
genotype of IGF-1. The authors concluded that the genotype of the IGF-1 promoter was 
different in young CRC patients compared to older CRC patients and that IGF-1 SNP was 
associated with mucinous adenocarcinoma.  
Yantis et. al. (2009) provided data to show that post translational regulation of mRNA and 
subsequent protein expression may be particularly important to the development of CRC in 
young patients. They compared 24 patients <40 yrs of age with 45 patients  40 yrs of age, 
who served as controls. Cases were evaluated for clinical risk factors of malignancy and 
pathologic feature predictive of outcome. More aggressive features in tumours of young 
patients, namely more frequent lymphovascular (81%) and venous (48%) invasion, an 
infiltrative growth pattern (81%) were reported. Significantly increased expression of miR-
21, miR-20a, miR-145, miR-181b, and miR-203 was noted in the younger group.  
6. Predisposing factors 
Family history of CRC at a young age is a significant risk factor. Johns and Houlston (2001) 
performed a meta-analysis of 27 case-control and cohort studies of colorectal cancer risk and 
found that a family history of one affected first degree relative diagnosed before the age of 
45 carried a 3. 87 fold (95% confidence interval 2. 40 – 6. 22) increased risk for the disease. 
Fuchs et. al. (1994) concluded that a family history of CRC is associated with an increased 
risk of disease, especially amongst the young. The relative risk factor of an under-45 yrs 
person with one or more affected first degree relative as compared with those without a 
family history was 3. St. John et. al. (1993) performed a case-control study of relatives of 
CRC patients and of matched control patients. They concluded that first degree relatives of 
patients with CRC have an increased risk of colorectal cancer. The risk was greater if 
diagnosed at an early age and when other first degree relatives were affected. Winawer et. 
al. (1996) observed that siblings and parents of patients with adenomatous polyps were at 
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an increased risk for CRC particularly when adenoma was diagnosed at < 60 yrs age. 
Despite limited accuracy and compliance, family history is still the most easily obtainable 
risk factor for colorectal cancer.  
Deficiency in host response to carcinogenesis is less easily recognized and treated. A 
personal history of other cancers, especially chronic immunosensitive cancers such as 
melanoma, if occurring at a young age, may indicate an increased susceptibility to CRC. 
Chronic immune suppression or clinical suggestions of impaired immunity may also mean 
the same.  
FAP and HNPCC patients have a lifetime risk of 100 and 80 percent respectively, of 
developing CRC. In FAP, the affected persons develop hundreds to thousands of colonic 
polyps. Although the rate of transition to cancer is slow, the vast number of polyps virtually 
assures colon cancer development at a young age. Average age of developing cancer is 39 
years, with 7% diagnosed by the age of 20 and 15% by 25. In HNPCC, the affected persons 
have a very high risk for CRC but do not develop the hundreds of polyps seen in FAP. 
These polyps are very likely to make a transition to cancer. Although sporadic colon cancer 
usually arises in colon polyps after a 5-10 years period of growth and transformation, in 
HNPCC this progression can occur within 1 -2 years. HNPCC occurs at a relatively young 
age, median 42-45 years, with 35%-40% diagnosed before 40 years of age. The proportion of 
HNPCC or familial colorectal cancer among all CRC varies by country from 1-10% with a 
median of 2-5% (Mecklin and Ponz de Leon 1994). HNPCC has been reported from many 
different populations, Europeans, white and Indian Americans, Asians, Australasians, South 
Americans and Egyptians (Sarroca et. al. 1978; Bamezai et. al. 1984; Ushio 1985; Lynch et. al. 
1985; Mecklin 1987; Vasen et. al. 1990; Mecklin and Jarvinen 1991; Jass and Stewart 1992; 
Soliman et. al. 1998).  
Ulcerative colitis (UC) is another important predisposing factor. The most important risk 
factors for development of CRC in UC patients are prolonged duration of disease, 
pancolonic disease, continuously active disease and severity of inflammation. Eaden et. al. 
(2001) performed a meta-analysis of the risk of CRC in UC. 116 of 194 reported studies were 
included in this analysis. Overall prevalence of CRC in UC patients was 3. 7%. The risk of 
CRC in UC patients was determined by decade of disease and a non significant increase in 
risk over time was observed.  
7. Prognosis and survival of young patients 
Opinion on the issue of survival of younger patients is not unanimous. We have divided 
literature reports on this issue, pre-2000 and post-2000, in two separate sections. The reports 
in which prognosis for the young is shown to be poorer and the ones in which they are not 
so, are separately grouped.  
Pre-2000, poor prognosis: Moore et. al. (1984) concluded that poorer survival in younger 
(<40 years) patients was a result of an inherently more virulent lesion, a conclusion 
supported by a greater incidence of mucinous tumours, an indicator of poor prognosis and a 
higher incidence of advanced disease, especially in the second and third decades. They did 
not find delay in diagnosis as an important factor in determination of survival. Adkins et. al. 
(1987) ascribed poorer prognosis in the young (<35 years) to unfavourable histological 
features of the tumours and advanced disease at the time of presentation in these patients. 
Of 45 under-35 patients, 19 patients with poorly differentiated tumours survived for an 
average of 1 year, whereas 19 with well or moderately differentiated tumours survived for 
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an average of 4. 5 years. Those few patients who presented early in the course of their 
disease responded well to radical resection. Okuno et. al. (1987) reported frequent 
occurrence of mucinous carcinoma, lymph node involvement and advanced stage according 
to Dukes’ classification in the younger group (<39 years). The overall survival rate was 
poorer in the younger group (41% vs. 55. 9%), whereas the difference between the two 
groups in rates of curative resection was not statistically significant.  
Pre-2000, favourable prognosis: Howard et. al. (1975) found that younger patients had a 
greater frequency of advanced signs, later stages of cancer and mucoid carcinoma, but when 
compared by clinical stage, they did as well or better than older patients. 5-year survival 
rates were 31% in <40 years group and 32% in>40 years group. Clinical staging was the 
most important prognostic factor irrespective of age. No inherent difference was found in 
the virulence of cancer in the young, survival rate being essentially the same. Adloff et. al. 
(1986) in a paper published much later reached identical conclusion. Walton et. al. (1976) in 
a study on 70 under-40 patients reported that survival time was shorter in patients with 
mucinous and anaplastic tumours and their incidences increased in this age group. Overall 
survival rates, however, did not significantly depend on age. Early diagnosis and prompt 
aggressive surgical treatment produced survival equivalent to that in patients of other age 
groups. Scarpa et. al. (1976) in a study on 47 adults in the age group 20-40 years found 
smaller tumours and depth of invasion as important prognostic factors but tumour grade 
had no correlation with survival. They concluded that there was no difference in survival 
rate between the young and the old. Bulow (1980) found, in an extensive study spread over 
25 years (951 <40 patients, all <40 patients in Denmark in the period 1943-1967) that stage 
according to Dukes’ classification and presence of intestinal obstruction and/or perforation 
and not age, determined prognosis. Ahlberg et. al. (1980) in a study group of 27 patients, 
aged <30 years, in 1969-70 in Scandinavia, concluded that prognosis was good, if 
predisposing factors were absent (9/15 survived 5 years), but not so otherwise. Ohman 
(1982) in a study group of 1061 patients, of whom 48 were below 40, in Sweden reported a 
five year survival rate in the overall population and in curable cases. Both rates were equal 
in the two age groups. Age factor had no impact. Five year survival was 100% in stage A, 
50% in B, 33% in C. Proportion of Dukes’ A lesion was equal in the two groups; there were 
fewer B and more C lesions amongst the young. Survival was not altered if ulcerative colitis 
was superimposed on carcinoma. Beckman et. al. (1984) studied 69 patients, 20-39 years and 
reported good prognosis. Neither age, sex, tumour size, location, mere presence of lymph 
node metastases, depth of tumour invasion nor predisposing disease of the colon was a 
strong prognostic factor. Metastases of six or more lymph nodes and distant spread of the 
tumour at the time of initial surgery were ominous findings; so was mucinous carcinoma, a 
relatively frequent occurrence. Jarvinen and Turunen (1984) in a study on 249 under-40 year 
patients between 1970 and 1979 found no difference in their 5 year survival rate from that of 
the general population. A premalignant condition was more common as age decreased. 
Family cancer syndrome, FAP and other predisposing diseases were observed in a 
significant proportion of study group. It was suggested that more emphasis should be 
placed on identification, family screening and treatment of conditions predisposing to 
colorectal cancer. LaQuaglia et. al. (1992) analysed their experience with 29 histologically 
verified cases of whom 20 were resected for cure. The predictors for survival were 
resectability, regional nodal involvement, depth of invasion, grade (Signet ring (45%) or 
anaplastic lesions (24%) were considered high grade) and interval from symptom onset to 
diagnosis. Median age at diagnosis was 19 years (10-21 years), median survival was 16 
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months, that for those undergoing complete resection was 33 months. In those undergoing 
resection for cure, tumour grade, regional nodal involvement and depth of invasion were 
the only factors that affected prognosis. Hidalgo (1995) in Spain studied 26, under-45 CRC 
patients (17. 2% of the whole group) whose potential risk factors were no different from 
those of the general population. Clinical presentation, tumour site and Dukes’ stage were 
similar in the younger group and in the general population, but morbidity, mortality and 
post operative complications were lower. There were no differences in resection or survival 
rates. Chung et.al. (1998) in a study on 101 under 40 patients and 2064 older patients found 
no difference in tumour characteristics, Dukes’ stage and overall 5 year survival, but 
reported a higher adjusted hazard ratio and adverse outcome in the <40 years group 
compared to 40-59 years group. They noted that a significant family history and 
predisposing conditions in the young warrants aggressive screening, surveillance and 
treatment. Heys et. al. (1994) in a review reported histological evaluations of the cancers in 
the younger age group patients and found that approximately four times as many tumours 
were of the mucinous type. This was associated with an increased risk of local recurrence. 
Dukes’ staging and vascular invasion by tumour were prognostic indicators for overall 
patient survival. However survival rates for young patients with CRC were comparable to 
those of older patients, when equivalent Dukes’ stage was considered.  
Post-2000, favourable prognosis: O’Connell et. al. (2004b) used SEER (Surveillance, 
Epidemiology and End Results) database in the period 1991-1999 in the USA (1334 
younger patients, 20-40 years; 46,457 older patients 60-80 years) to conclude that 5-year 
stage-specific survival was similar for stage I and III patients and better for younger 
patients in stage II and IV (p<0. 01). The same patient group showed later stage (more of 
stage III and IV) and higher grade tumours for younger patients. The authors noted that 
their population-based finding contradicts earlier single institution reports. Stigliano et. 
al. (2008) compared a cohort of 40 HNPCC cases with 573 sporadic CRC cases in the 
period 1970-1993. Median age of diagnosis was 46. 8 years in HNPCC cases and 61 years 
in sporadic CRC cases. Early stage cancer (Dukes’ A & B) was 70% in HNPCC group and 
61. 6% in sporadic group. The crude 5-year cumulative survival for primary CRC was  
94. 2% in HNPCC vs. 75. 3% in sporadic cancer patients (p < 0. 0001). The influence of age 
on prognosis is apparent.  
Berg et. al. (2010) studied 181 patients (45, < 50 yr; 67 (51-70 yr); 69, > 70 yr) and found no 
difference in survival while comparing age groups, even when adjustment for tumour stage at 
diagnosis had been made. Younger patients however presented at a more advanced disease 
stage (54, 46, and 36% in three groups). Tumour stage was the most powerful prognostic 
variable (p < 0. 001). Turkiewicz et.al. (2001) in a study spanning 29 years in Australia 
concluded that young patients with CRC had the potential to do just as well. The overall 5-
years survival among younger patients in Stage A and B (53%) was found to be better than 
their counterparts in the older group. With influence of a family history of CRC being very 
apparent in this group, the authors conclude that emphasis must be on screening. Makela et. 
al. (2002) in a study of 102 under-50 patients in Finland over a 20 years period (1980-1999) 
concluded that young age is not a poor prognostic marker in colorectal cancer. Radical 
operation, venous invasion and tumour grade were good predictors of survival in patients 
below 50 years. Kam et.al. (2004) in a study in Singapore on 39 under-30 years patients inferred 
that age did not affect survival and recommended early endoscopy for all with persistent 
symptoms. They concluded that early diagnosis, radical resection and adjuvant therapy still 
form the cornerstone in management of colorectal cancer in this age group. Karsten et.al. 
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(2008) in the USA performed a comparative study of two groups, < 40 years and > 60 years of 
age, ethnically diverse, between 1998 and 2005. Fifty one percent of 41 young patients were 
Hispanic. Young patients were more likely to have a family history. Aggressive nature of 
tumour in the young was noted, but operative intervention and survival was similar in the 
two groups. Tohme et. al. (2008) in a study of 325 patients, 13. 2% of whom were below 45 
concluded that age by itself was not a significant prognostic factor. The independent 
prognostic factors were delay in consultation, which was more frequent in younger patients 
(29. 7 vs. 18. 6 weeks, p=0. 01), positive family history in the young (44. 1% vs. 18. 2%), right 
sided tumour and peritoneal carcinomatosis. Leff et. al. (2010) in a British study of 49, <40 
patients reported a 5-year and overall survival of 58% and 46% respectively. They concluded 
that prognosis in the young was not worse than that for CRC in the population as a whole. 
Mitry et. al. (2001) reported, in both overall and stage for stage comparisons that patients 
below the age of 45 years had a better survival rate than older patients, mortality rate was 
lower in the younger group (2. 1% vs. 8. 4%) although advanced stage presentation was more 
frequent and predisposing conditions were significantly higher in the below 45 group (11. 7 vs. 
0. 4%, p<0. 001). Lin et. al. (2005) studied 45 histologically confirmed under-40 patients, 90% of 
whom reported with advanced (C+D) stage, between 1992-2002 in Taiwan. They reported that 
disease stage was an important prognostic factor, 5 year survival in B, C and D stage patients 
being 25, 16, and 0% respectively. Karnofsky performance status (KPS  70%), lymph node 
involvement and preoperative LDH levels were major determinants of survival. Surgical 
resection and adjuvant chemotherapy improved survival of advanced stage patients, but the 
improvement achieved does reach the level of a patient who reports early. Liang et. al. (2003) 
reported that although the younger patients with colorectal cancer had more mucin producing 
(14. 7 vs. 4. 7%, p<0. 001) tumours and a more advanced tumour stage at presentation (p<0. 
001) than older patients, the operative mortality rate was lower (0. 7 vs. 5%) and cancer specific 
survival was similar (p<0. 05) in stage I, II, III disease or better in stage IV disease (22-28 vs. 12-
17 months, p< 0. 001).  
Post-2000, poor prognosis: Endreseth et. al. (2006) in a study on 2283 rectal cancer 
patients found overall 5-year survival to be 54% for patients younger than 40 years 
compared to 71-88% for the older patients (p=0. 029). Among those treated for cure, 56% 
of <40 group developed distant metastasis compared to 20-26% in the older group. Age 
younger than 40 years was a significant prognostic factor in this group and increased the 
risk of metastasis and death. A study from Nepal by Singh et. al. (2002a) reported a more 
aggressive disease in the younger group (<40 years) and a significantly lower 2 years 
survival rate (4% vs. 55%). Singh et. al. (2002b)in a study on 18 under 40 patients in India 
found that the tumor was unresectable in 5 patients (28%). Fourteen patients (78%) had 
advanced cancer indicated by TNM stage III or IV disease. Among the 13 patients 
subjected to surgical treatment followed by adjuvant chemotherapy, only 3 had long term 
disease free survival beyond 2 years.  
Prognosis and Genetics: There have been reports in the literature that suggest that the 
survival of MSI-H CRC patients is longer than that of patients with MSS CRC. This latter 
group constitutes the majority. In some studies however no survival advantage was 
detected and a National Cancer Institute workshop held in 1998 (Boland et. al. 1998) 
concluded that MSI had not been shown to be an independent predictor of prognosis (Gryfe 
et. al., 2000). We cite a number of mostly post-2000 papers that link prognosis to MSI tumour 
pathway.  
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Gryfe et. al. (2000), in a study on 607 under-50 patients found MSI in 17% of patients and 
concluded that MSI was associated with a significant survival advantage independent of all 
standard prognostic factors including tumour stage. Regardless of depth of tumour 
invasion, MSI-H CRC had a decreased likelihood of metastasis to regional lymph nodes. 
Elsaleh et. al. (2000) (mean age 66. 7±12. 9 years) in Australia report striking survival 
benefits for patients with MSI tumours (90 vs 35%, p=0. 0007) and also for patients with 
right sided lesions, who received adjuvant chemotherapy as compared to those who did not 
(48 vs 27% alive at end of study, p<0. 0001) and for women (53 vs 33%, p<0. 0001). Suh et. al. 
(2002) in a comparative study of MSI(+) and MSI(-) sporadic young (<40years) CRC patients 
showed that the former had better prognosis (p=0. 051). Their results suggested that 
sporadic MSI(+) CRC in the young had different histomorphologic features as compared to 
MSI(-) CRC and HNPCC cancers. Samowitz et. al. (2009)in a study of 990 rectal cancer 
patients in the US showed that even though MSI-H has been associated in many studies 
with improved prognosis of colon cancer, the effect of MSI-H and K-ras mutations posed 
significantly higher risk of death for rectal cancers. Liang et. al. (2003) reported that there 
was a higher percentage of normal p53 expression (61 vs. 48%) and high frequency 
microsatellite instability (MSI-H) (29. 4 vs. 6. 3%, p, 0. 001) in the young. Lukish et. al. (1998) 
in a study group of 36 patients in the <40 year age group determined their DNA replication 
error (RER) status (expressed as MSI) and compared the clinical and pathologic 
characteristics of RER(+) and RER(-) cases. They concluded that RER(+) tumours were 
common (47%) in young patients and patients with RER(+) tumours had a significantly 
improved prognosis:5 year survival probability 68% in RER(+), 32% in RER () tumours 
(p<0. 05). Knowledge of RER status therefore could affect initial therapy, postoperative 
chemotherapy and follow up.  
The paradoxical good survival after surgery for patients with young age at diagnosis of CRC 
supports the idea that many cancers in the young are microsatellite unstable. A number of 
studies linked high frequency MSI to poor tumour differentiation or mucinous histology, a 
signature of many tumours in the young (Sanchez et. al. 2009; Kim et. al. 1994, Lin et. al 
2010, Suh et. al., 2002). Ionov et. al. (1993) in their study of mutations involving poly (dA. 
dT) sequences (Section 5 for details) found that the presence of mutations was accompanied 
by an increase in the proportion of poorly differentiated lesions (6/9 vs 17/90, poor/well, 
moderate)and also in an increase in proportion of Stage A +B disease (2/14 vs 53/68; 
C+D/A+B). Crude survival was expected to be better than usual in young patients because 
of their youth and the improved tolerance to surgery and complications that youth confers 
(Liang and Church 2010).  
Berg et. al. (2010) in a study of patients in different age groups (Section 5 for details), found 
that patients with TP53 mutated tumours had poorer survival rates than patients with wild 
type TP53 (938 vs. 1016 days, p =0. 04); however the difference was not significant when 
corrected for tumour stage. TP53 mutation were of higher prognostic significance in right 
sided tumours (883, 1051 days; mutated, wild type; p = 0. 005). Among patients in the 
younger age group, those with K-ras mutation had significantly shorter survival than 
patients with K-ras wild type samples (841, 1033 days, p=0. 02).  
Barnetson et. al. (2006) studied a group of 870 below-55 years CRC patients for germline 
mutations in DNA MMR genes, proposed a model for prediction of the presence of 
mutations in these genes and validated the model in an independent group of 155 patients. 
Survival in carriers and non carriers was similar.  
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8. Molecular genetics and treatment protocol 
Chemotherapeutic treatment protocol will progressively become more specific as the genetic 
basis of CRC gets better understood and the heterogeneity of the disease is better 
characterized. There are several literature reports that show these connections.  
Fallik et. al. (2003) studied response to irinotecan in 72 patients, of whom 1 responded 
completely and 11 partially. Among the 7 tumours that displayed MSI-H phenotype, 4 
responded to irinotecan whereas only 7 out of 65 MSI-L tumours did (p=0. 009). A better 
response to irinotecan was observed in the patients whose tumours have lost BAX 
expression (p<0. 001). 7 of 72 tumours had inactivating mutations in the coding repeat of the 
target genes. Amongst these seven, five responded to irinotecan, whereas only 6 of the other 
65 tumours did (p<0. 001) indicating that MSI-driven inactivation of target genes modifies 
tumour sensitivity. It has been shown that tumours with mucinous histology, a common 
feature of many tumours in the young(section 7) and whose molecular genetic signatures 
have been referred to earlier (section 3), show poor response to fluorouracil-based first line 
chemotherapy (Negri et. al. 2005) and first-line oxaliplatin /irinotecan based combination 
chemotherapy (Catalano et. al. 2009).  
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